BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37605345)

  • 1. Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy.
    Karolová J; Kazantsev D; Svatoň M; Tušková L; Forsterová K; Maláriková D; Benešová K; Heizer T; Dolníková A; Klánová M; Winkovska L; Svobodová K; Hojný J; Krkavcová E; Froňková E; Zemanová Z; Trněný M; Klener P
    Am J Hematol; 2023 Oct; 98(10):1627-1636. PubMed ID: 37605345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.
    Hill HA; Qi X; Jain P; Nomie K; Wang Y; Zhou S; Wang ML
    Blood Adv; 2020 Jul; 4(13):2927-2938. PubMed ID: 32598477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
    Delfau-Larue MH; Klapper W; Berger F; Jardin F; Briere J; Salles G; Casasnovas O; Feugier P; Haioun C; Ribrag V; Thieblemont C; Unterhalt M; Dreyling M; Macintyre E; Pott C; Hermine O; Hoster E;
    Blood; 2015 Jul; 126(5):604-11. PubMed ID: 26022239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
    Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E
    Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma.
    Tashkandi H; Petrova-Drus K; Batlevi CL; Arcila ME; Roshal M; Sen F; Yao J; Baik J; Bilger A; Singh J; de Frank S; Kumar A; Aryeequaye R; Zhang Y; Dogan A; Xiao W
    Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31395597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
    Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
    Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.
    Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P
    Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent
    Malarikova D; Berkova A; Obr A; Blahovcova P; Svaton M; Forsterova K; Kriegova E; Prihodova E; Pavlistova L; Petrackova A; Zemanova Z; Trneny M; Klener P
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
    Wu C; de Miranda NF; Chen L; Wasik AM; Mansouri L; Jurczak W; Galazka K; Dlugosz-Danecka M; Machaczka M; Zhang H; Peng R; Morin RD; Rosenquist R; Sander B; Pan-Hammarström Q
    Oncotarget; 2016 Jun; 7(25):38180-38190. PubMed ID: 27224912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.
    Kawashima I; Oishi N; Kasai K; Inoue T; Hosokawa E; Nakadate A; Matsuura M; Kumagai T; Koshiishi M; Yamamoto T; Nakajima K; Tanaka M; Kondo T; Kirito K
    Virchows Arch; 2022 May; 480(5):1101-1105. PubMed ID: 34226971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.
    Hansen MH; Cédile O; Blum MK; Hansen SV; Ebbesen LH; Bentzen HHN; Thomassen M; Kruse TA; Kavan S; Kjeldsen E; Kristensen TK; Haaber J; Abildgaard N; Nyvold CG
    Exp Hematol; 2020 Apr; 84():7-18.e12. PubMed ID: 32173361
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic landscape and prognostic analysis of mantle cell lymphoma.
    Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
    Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
    Ma X; Edmonson M; Yergeau D; Muzny DM; Hampton OA; Rusch M; Song G; Easton J; Harvey RC; Wheeler DA; Ma J; Doddapaneni H; Vadodaria B; Wu G; Nagahawatte P; Carroll WL; Chen IM; Gastier-Foster JM; Relling MV; Smith MA; Devidas M; Guidry Auvil JM; Downing JR; Loh ML; Willman CL; Gerhard DS; Mullighan CG; Hunger SP; Zhang J
    Nat Commun; 2015 Mar; 6():6604. PubMed ID: 25790293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
    Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
    Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.
    Jeong S; Park YJ; Yun W; Lee ST; Choi JR; Suh C; Jo JC; Cha HJ; Jeong JY; Chang H; Cha YJ; Kim H; Park MJ; Song W; Cho EH; Jeong EG; Lee J; Park Y; Lee YS; Kim DJ; Lee HS
    Sci Rep; 2020 Aug; 10(1):13359. PubMed ID: 32770099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.